Canaccord Genuity Group Cuts Evolent Health (NYSE:EVH) Price Target to $6.00

Posted by Francis Steltz on Aug 13th, 2026

Evolent Health (NYSE:EVH – Free Report) had its price objective cut by Canaccord Genuity Group from $7.00 to $6.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the technology company’s stock.

Several other research firms have also weighed in on EVH. TD Cowen reduced their target price on shares of Evolent Health from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Truist Financial downgraded Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a report on Tuesday, June 30th. Citigroup reissued a “sell” rating and issued a $6.75 price objective (up from $5.50) on shares of Evolent Health in a research report on Thursday, July 23rd. Needham & Company LLC boosted their price objective on Evolent Health from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings raised Evolent Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 4th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Evolent Health currently has an average rating of “Moderate Buy” and an average price target of $5.96.

Get Our Latest Stock Report on EVH

Evolent Health Trading Up 2.0%

NYSE EVH opened at $4.18 on Monday. Evolent Health has a one year low of $2.10 and a one year high of $10.08. The company’s 50 day moving average price is $4.76 and its 200 day moving average price is $3.72. The company has a debt-to-equity ratio of 2.52, a quick ratio of 1.24 and a current ratio of 1.24. The firm has a market capitalization of $470.17 million, a price-to-earnings ratio of -0.91 and a beta of 0.79.

Evolent Health (NYSE:EVH – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The firm had revenue of $484.50 million for the quarter, compared to analysts’ expectations of $597.70 million. During the same period in the previous year, the company posted ($0.10) earnings per share. Evolent Health’s revenue was up 46.9% compared to the same quarter last year. On average, sell-side analysts predict that Evolent Health will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Evolent Health

Large investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC increased its stake in Evolent Health by 4,000.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after buying an additional 4,000 shares during the period. Strs Ohio purchased a new position in Evolent Health in the 1st quarter valued at about $47,000. Headlands Technologies LLC acquired a new stake in shares of Evolent Health during the second quarter valued at about $58,000. Quantbot Technologies LP acquired a new stake in shares of Evolent Health during the third quarter valued at about $88,000. Finally, Caxton Associates LLP purchased a new stake in shares of Evolent Health during the third quarter worth about $93,000.

Evolent Health Company Profile

(Get Free Report)

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.